Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus

Arthritis Research and Therapy

Volumn 8, Issue 1, 2006, Pages

  Lenert, Petar S ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; DNA; RHEUMATOID FACTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; ANTISENSE OLIGONUCLEOTIDE;

ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TYPE; CELLULAR DISTRIBUTION; CPG ISLAND; CROSS REACTION; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA SEQUENCE; HUMAN; INNATE IMMUNITY; MOLECULAR MECHANICS; NONHUMAN; ONTOGENY; PATHOGENESIS; PLASMA CELL; PROTEIN LOCALIZATION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; AUTOIMMUNITY; B LYMPHOCYTE; GENETICS; IMMUNOLOGY; LUPUS VULGARIS; METABOLISM; SIGNAL TRANSDUCTION;

AUTOIMMUNITY; B-LYMPHOCYTES; DENDRITIC CELLS; HUMANS; LUPUS VULGARIS; OLIGONUCLEOTIDES, ANTISENSE; PLASMA CELLS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 33144467291     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1888     Document Type: Review

References (134)

1. Abreu MT, Fukata M, Arditi M: TLR signaling in the gut in health and disease. J Immunol 2005, 174:4453-4460.
2. Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol 2003, 21:335-376.
3. Barton GM, Medzhitov R: Toll-like receptors and their ligands. Curr Top Microbiol Immunol 2002, 270:81-92.
4. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K, Mudd S, Shamel L, Sovath S, Goode J, et al: Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci USA 2004, 101:3516-3521.
5. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, et al.: A toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
6. Hoebe K, Janseen E, Beutler B: The interface between innate and adaptive immunity. Nat Immunol 2004, 5:971-974.
7. Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680.
8. Chu RS, Askew D, Harding C: CpG DNA switches on Th1 immunity and modulates antigen-presenting cell function. Curr Top Microbiol Immunol 2000, 247:199-210.
9. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM: CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon γ. J Immunol 1996, 93:2879-2883.
10. Poeck H, Wagner M, Battiany J, Rothenfusser S, Wellisch D, Hornung V, Jahrsdorfer B, Giese T, Endres S, Hartmann G: Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 2004, 103:3058-3064.
11. Banchereau J, Pascual V, Palucka AK: Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004, 20:539-550.
12. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
13. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J: Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001, 294:1540-1543.
14. Balazs M, Martin F, Zhou T, Kearney JF: Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 2002, 17:341-352.
15. Dubois B, Vanbervliet B, Fayette J, Massacrier C, Van Kooten C, Briere F, Banchereau J, Caux C: Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes. J Exp Med 1997, 185:941-951.
16. Dubois B, Massacrier C, Vanbervliet B, Fayette J, Briere F, Banchereau J, Caux C: Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes. J Immunol 1998, 161:2223-2231.
17. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J: Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19:225-234.
18. Braun D, Caramalho I, Demengeot J: IFN-α/β enhances BCR-dependent B cell responses. Int Immunol 2002, 14:411-419.
19. Ronnblom L, Alm VG: Systemic lupus erythematosus and type I interferon system. Arthritis Res Ther 2003, 5:68-75.
20. Oldstone MB: Molecular mimicry and immune-mediated diseases. FASEB J 1998, 12:1255-1265.
21. Anders HJ: A toll for lupus. Lupus 2005, 14:417-422.
22. Lenert P, Goeken A, Handwerger BS, Ashman RF: Innate immune responses in lupus-prone Palmerston North mice: differential responses to LPS and bacterial DNA/CpG oligonucleotides. J Clin Immunol 2003, 23:202-213.
23. Lenert P: Inhibitory oligodeoxynucleotides: therapeutic promise for systemic autoimmune diseases? Clin Exp Immunol 2005, 140:1-10.
24. Leadbetter EA, Rifkin AR, Hohlbaum AM, Beaudette BC, Schlomchik MJ, Marshak-Rothstein A: Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002, 416:603-607.
25. Vallin H, Perers A, Alm GV, Ronnblom L: Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus. J Immunol 1999, 163:6306-6313.
26. Viau M, Zouali M: B-lymphocytes, innate immunity, and autoimmunity. Clin Immunol 2005, 114:17-26.
27. Krieg AM: CpG DNA: a pathogenic factor in systemic lupus erythematosus. J Clin Immunol 1995, 15:284-292.
28. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A: Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005, 204:27-42.
29. Blank M, Shoenfeld Y: Experimental models of systemic lupus erythematosus: anti-dsDNA in murine lupus. Rheumatology 2005, 44:1086-1089.
30. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y: Autoantibody explosition in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004, 34:501-537.
31. Mohan C, Adams S, Stanik V, Datta SK: Nucleosome: a major immunogen for the pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993, 177:1367-1381.
32. Mevorach D, Zhou JL, Song X, Elkon KB: Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998, 188:387-392.
33. Radic MZ, Weigert M: Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu Rev Immunol 1994, 12:487-520.
34. Tan EM: Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989, 44:93-151.
35. Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994, 179:1317-1330.
36. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G: Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168:4531-4537.
37. Zarember KA, Godowski PJ: Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products and cytokines. J Immunol 2002, 168:554-561.
38. Naka T, Fujimoto M, Tsutsui H, Yoshimura A: Negative regulation of cytokine and TLR signalings by SOCS and others. Adv Immunol 2005, 87:61-122.
39. Lenert P, Brummel R, Field EH, Ashman RF: TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol 2005, 25: 29-40.
40. - APC in mouse spleen. J Immunol 2004, 173:2362-2372.
41. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM: B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002, 3:944-950.
42. Ku CL, Yang K, Bustamante J, Puel A, von Bernuth H, Santos OF, Lawrence T, Chang HH, Al-Mousa H, Picard C, et al.: Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunol Rev 2005, 203:10-20.
43. Johnson GB, Brunn GJ, Platt JL: Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol 2003, 23:15-44.
44. Seong SY, Matzinger P: Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004, 4:469-478.
45. Vabulas RM, Wagner H, Schild H: Heat shock proteins as ligands of toll-like receptors. Curr Top Microbiol Immunol 2002, 270:169-184.
46. Seery JP: IFN-γ transgenic mice: clues to the pathogenesis of systemic lupus erythematosus? Arthritis Res Ther 2000, 2: 437-440.
47. Theofilopoulos AN, Koundouris S, Kono DH, Lawson BR: The role of IFN-γ in systemic lupus erythematosus: a challenge to the Th1 /Th2 paradigm in autoimmunity. Arthritis Res Ther 2001, 3:136-141.
48. Cerutti A, Qiao X, He B: Plasmocytoid dendritic cells and the regulation of immunoglobulin heavy chain class switching. Immunol Cell Biol 2005, 83:554-562.
49. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL: Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979, 301:5-8.
50. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J: Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982, 216: 429-431.
51. Bengtsson A, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, Ronnblom L: Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not antiretroviral antibodies. Lupus 2000, 9:664-671.
52. Ytterberg SR, Schnitzer TJ: Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982, 25: 401-406.
53. Ronnblom LE, Alm GV, Oberg KE: Possible induction of systemic lupus erythematosus by interferon-a treatment in a patient with a malignant carcinoid tumor. J Intern Med 1990, 227:207-210.
54. Ioannou Y, Isenberg DA: Current evidence for the induction of autoimmune rheumatic conditions by cytokine therapy. Arthritis Rheum 2000, 43:1431-1442.
55. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, et al.: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003, 100:2610-2615.
56. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723.
57. Ronnblom L, Alm GV: An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 2001, 22:427-431.
58. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR: Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004, 199:1631-1640.
59. Lian ZX, Kikuchi K, Yang GX, Ansari AA, Ikehara S, Gershwin ME: Expansion of bone marrow IFN-alpha-producing dendritic cells in New Zealand Black [NZB] mice: high level expression of TLR9 and secretion of IFN-alpha in NZB bone marrow. J Immunol 2004, 173:5283-5289.
60. Dalod M, Salazar-Mather TP, Malmgaard L, Lewis C, Asselin-Paturel C, Briere F, Trinchieri G, Biron CA: Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J Exp Med 2002, 195:517-528.
61. Colonna M, Trinchieri G, Liu YJ: Plasmocytoid dendritic cells in immunity. Nat Immunol 2004, 5:1219-1226.
62. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G: Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmocytoid dendritic cells. Eur J Immunol 2001, 31:2154-2163.
63. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM: Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J Immunol 2001, 166:2372-2377.
64. Carpenter DF, Steinberg AD, Schur PH, Talal N: The pathogenesis of autoimmunity in New Zealand mice. II. Acceleration of glomerulonephritis by polyinosinic-polycytidylic acid. Lab Invest 1970, 23:628-634.
65. Braun D, Geraldes P, Demengeot J: Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003, 20:15-25.
66. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, Theofilopoulos AN: Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003, 197:777-788.
67. Hron JD, Peng SL: Type I IFN protects against murine lupus. J Immunol 2004, 173:2134-2142.
68. Pawar RD, Patole PS, Zecher D, Segerer S, Kretzler M, Schlondorff D, Anders HJ: Toll-like receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol 2005 [Epub ahead of print].
69. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB: Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001, 98:9237-9242.
70. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
71. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
72. Vollmer J, Weeratna RD, Jurk M, Samulowitz U, McCluskie MJ, Payette P, Davis HL, Schetter C, Krieg AM: Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology 2004, 113:212-223.
73. Marshall JD, Fearon KL, Higgins D, Hessel EM, Kanzler H, Abbate C, Yee P, Gregorio J, Cruz TD, Lizcano JO, et al.: Superior activity of the type C class of ISS in vitro and in vivo across multiple species. DNA Cell Biol 2005, 24:63-72.
74. Lenert P, Goeken JA, Ashman RF: Extended sequence preferences for oligodeoxyribonucleotide activity. Immunology 2006:in press.
75. Kerkmann M, Costa LT, Richter C, Rothenfusser S, Battiany J, Hornung V, Johnson J, Englert S, Ketterer T, Heck W, et al.: Spontaneous formation of nucleic acid-based nanoparticules is responsible for high interferon-α induction by CpG-A in plasmocytoid dendritic cells. J Biol Chem 2005, 280:8086-8093.
76. Marshall JD, Fearon K, Abbate C, Subramanian S, Yee P, Gregorio J, Coffman RL, Van Nest G: Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol 2003, 73:781-792.
77. Hartmann G, Battiany J, Poeck H, Wagner M, Kerkmann M, Lubenow N, Rothenfusser S, Endres S: Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol 2003, 33:1633-1641.
78. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM: Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004, 34:251-262.
79. Gilkeson GS, Ruiz P, Pippen AM, Alexander AL, Lefkowith JB, Pisetsky DS: Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA. J Exp Med 1996, 183:1389-1397.
80. Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, de Lema GP, Strutz F, Bauer S, Rutz M, Wagner H, et al.: Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 2004, 18:534-536.
81. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ: Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005, 202:321-331.
82. Krieg AM, Steinberg AD: Analysis of thymic endogenous retroviral expression in murine lupus. Genetic and immune studies. J Clin Invest 1990, 86:809-816.
83. Pender MP: Infection of autoreactive B cells with EBV, causing chronic autoimmune diseases. Trends Immunol 2003, 29: 3168-3178.
84. Tan EM, Schur PH, Carr RI, Kunkel HG: Deoxyribonucleic acid DNA and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 1966, 45:1732-1740.
85. Stacey K, Young GR, Clark F, Sester DP, Roberts TL, Naik S, Sweet MJ, Hume DA: The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J Immunol 2003, 170:3614-3620.
86. Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F, Klinman DM: Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol 2003, 171: 1393-1400.
87. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A: Activation of autoreactive B cells by CpG dsDNA. Immunity 2003, 19:837-847.
88. Sano H, Morimoto C: DNA isolated from DNA/anti-DNA antibody immune complexes in systemic lupus erythematosus is rich in guanine-cytosine content. J Immunol 1982, 128:1341-1345.
89. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M: Evidence of impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 1990, 33:1665-1673.
90. Richardson B: DNA methylation and autoimmune disease. Clin Immunol 2003, 109:72-79.
91. Bird AP: CpG islands as gene markers in the vertebrate nucleus. Trends Genet 1987, 3:342-347.
92. Brooks WH: Systemic lupus erythematosus and related autoimmune diseases are antigen-driven, epigenetic diseases. Med Hypotheses 2002, 59:736-741.
93. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR, et al.: RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005, 202:1171-1177.
94. Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, Wagner H, Bauer S: Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 2004, 34:2541-2550.
95. Monroe JG, Bannish G, Fuentes-Panana EM, King LB, Sandel PC, Chung J, Sater R: Positive and negative selection during B lymphocyte development. Immunol Res 2003, 27:427-442.
96. Cancro MP, Kearney JF: B cell positive selection: road map to the primary repertoire? J Immunol 2004, 173:15-19.
97. Grimaldi CM, Hicks R, Diamond B: B cell selection and susceptibility to autoimmunity. J Immunol 2005, 174:1775-1781.
98. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC: Predominant autoantibody production by early human B cell precursors. Science 2003, 301:1374-1377.
99. Yi AK, Peckham DW, Ashman RF, Krieg AM: CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. Int Immunol 1999, 11:2015-2024.
100. Erikson J, Radic MZ, Camper SA, Hardy RR, Carmack C, Weigert M: Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature 1991, 349:331-334.
101. Bendelac A, Bonneville M, Kearney JF: Autoreactivity by design: innate B and T lymphocytes. Nat Rev Immunol 2001, 1:177-186.
102. Martin F, Kearney JF: Marginal-zone B cells. Nat Rev Immunol 2002, 2:323-335.
103. Chen X, Martin F, Forbush KA, Perlmutter RM, Kearney JF: Evidence of selection of a population of multireactive B cells into the splenic marginal zone. Int Immunol 1997, 9:27-41.
104. Kenny JJ, Rezanka U, Lustig A, Fischer RT, Yoder J, Marshall S, Longo DL: Autoreactive B cells escape clonal deletion by expressing multiple antigen receptors. J Immunol 2000, 164: 4111-4119.
105. Li Y, Li H, Weigert M: Autoreactive B cells in the marginal zones that express dual receptors. J Exp Med 2002, 195:181-188.
106. Grimaldi CM, Michael DJ, Diamond B: Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol 2001, 167:1886-1890.
107. Moll T, Martinez-Soria E, Santiago-Raber ML, Amano H, Pihlgren-Bosch M, Marinkovic D, Izui S: Differential activation of anti-erythrocyte and anti-DNA autoreactive B lymphocytes by the Yaa mutation. J Immunol 2005, 174:702-709.
108. Brummel R, Lenert P: Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides. J Immunol 2005, 174:2429-2434.
109. He B, Qiao X, Cerutti A: CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 2004, 173:4479-4491.
110. Lenert P, Brummel R, Field EH, Ashman RF: TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol 2005, 25: 29-40.
111. Willenbrock K, Jungnickel B, Hansmann ML, Kuppers R: Human splenic marginal zone B cells lack expression of activation-induced cytidine deaminase. Eur J Immunol 2005, 35:3002-3007.
112. Srivastava B, Quinn WJ, Hazard K, Erikson J, Allman D: Characterization of marginal zone B cell precursors. J Exp Med 2005, 202:1225-1234.
113. Gatto D, Ruedl C, Odermatt B, Bachmann MF: Rapid response of marginal zone B cells to viral particles. J Immunol 2004, 173:4308-4316.
114. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O, Coffman RL: Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005, 202:1131-1139.
115. Peeva E, Zouali M: Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunol Lett 2005, 101:123-143.
116. Qiao B, Wu J, Chu YW, Wang Y, Wang DP, Wu HS, Xiong SD: Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocyte-derived DNA. Rheumatology 2005, 44:1108-1114.
117. Richardson BC: Role of DNA methylation in the regulation of cell function: autoimmunity, aging and cancer. J Nutr 2002, Suppl:2401S-2405S.
118. Yasuda K, Yu P, Kirschning CJ, Schlatter B, Schmitz F, Heit A, Bauer S, Hochrein H, Wagner H: Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and independent pathways. J Immunol 2005, 174:6129-6136.
119. Halpern MD, Pisetsky DS: In vitro inhibition of murine IFNγ production by phosphorothioate deoxyguanosine oligomers. Immunopharmacology 1995, 29:47-52.
120. Pisetsky DS, Reich CF: Inhibition of murine macrophage IL-12 production by natural and synthetic DNA. Clin Immunol 2000, 96:198-204.
121. Shirota H, Gursel M, Klinman DM: Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma-and IL-12-mediated signaling. J Immunol 2004, 173:5002-5007.
122. Krieg AM, Wu T, Weeratna R, Efler SM, Love-Human L, Yang L, Yi AK, Short D, Davis HL: Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA 1998, 95:12631-12636.
123. Chen Y, Lenert P, Weeratna R, McCluskie M, Wu T, Davis HL, Krieg AM: Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs. Gene Ther 2001, 8:1024-1032.
124. Klinman DM, Zeuner R, Yamada H, Gursel M, Currie D, Gursel I: Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides. Ann NY Acad Sci 2003, 1002:112-123.
125. Dong L, Ito S, Ishii KJ, Klinman DM: Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB × NZW mice. Arthritis Rheum 2005, 52:651-668.
126. Duramad O, Fearon KL, Chang B, Chan JH, Gregorio J, Coffman RL, Barrat FJ: Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol 2005, 174:5193-5200.
127. Stunz LL, Lenert P, Peckham D, Yi AK, Haxhinasto S, Chang M, Krieg AM, Ashman RF: Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol 2002, 32:1212-1222.
128. Lenert P, Rasmussen W, Ashman RF, Ballas ZK: Structural characterization of the inhibitory DNA motif for the type A[D]-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells. DNA Cell Biol 2003, 22:621-631.
129. Lenert P, Stunz L, Yi AK, Krieg AM, Ashman RF: CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-κB activation. Antisense Nuc Acid Drug Dev 2001, 11:247-256.
130. Lenert P, Yi AK, Krieg AM, Stunz L, Ashman RF: Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells. Antisense Nucl Acid Drug Dev 2003, 13:143-150.
131. Ashman RF, Goeken JA, Drahos J, Lenert P: Sequence requirements for oligodeoxyribonucleotides inhibitory activity. Int Immunol 2005, 17:411-420.
132. Patole PS, Zecher D, Pawar RD, Grone HJ, Schlondorff D, Anders HJ: G-rich DNA suppresses systemic lupus. J Am Soc Nephrol 2005, 16:3273-3280.
133. Lipsky PE: Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001, 2:764-766.
134. Keystone E: B cell targeted therapies. Arthritis Res Ther 2005, Suppl 3:S13-S18.